SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System..

加利福尼亚州南旧金山和圣地亚哥--（商业新闻短讯）--Twist Bioscience Corporation（纳斯达克：TWST），一家利用其硅平台提供高质量合成DNA，使客户获得成功的公司，以及Element Biosciences，Inc.，开创性技术的开发者，今天宣布合作开发Twist for Element，Element的AVITI的Exome 2.0 plus全面外显子组插入工作流程™ 系统。。

“Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally. Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

“Element继续扩大其客户群，为全球研究人员带来高质量和经济高效的测序。将Twist强大的NGS工作流程与Element的AVITI技术相结合，将为客户提供一种经济高效的下一代测序方法，”Twist Bioscience首席执行官兼联合创始人Emily M.Leproust博士说。

“Because our tools are sequencer agnostic, we can extend the reach of our products with innovative companies like Element, and continue our commitment to empowering researchers to accelerate breakthroughs in scientific discovery by providing advanced tools.”.

“由于我们的工具与测序仪无关，因此我们可以与Element等创新公司一起扩大产品的覆盖面，并继续致力于通过提供先进工具来授权研究人员加速科学发现的突破。”。

“We’ve laid out an ambitious product roadmap for 2024 to redefine what is possible on a sequencer and make it even easier for labs to produce the highest quality data at a low cost,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “With the Twist for Element Exome Workflow, we are able to provide our customers with easy access to Twist’s Exome 2.0 panel and high performing library preparation and target enrichment reagents, saving them potential downstream sequencing costs by reducing per sample sequencing requirements.”.

Element Biosciences首席执行官兼联合创始人莫莉·何（MollyHe）博士说：“我们已经为2024年制定了一个雄心勃勃的产品路线图，以重新定义测序仪的可能性，使实验室更容易以低成本产生最高质量的数据。”。“通过Twist for Element外显子组工作流程，我们能够为客户提供轻松访问Twist外显子组2.0面板和高性能文库制备和靶标富集试剂的机会，通过降低每个样品的测序要求，为他们节省潜在的下游测序成本。”。

The Twist for Element Exome Workflow is a purpose-built solution for Element’s AVITI chemistry, alleviating the need for additional workflow steps for linear library conversion. The workflow will include Twist’s library preparation and target enrichment bundled with the Exome 2.0 and comprehensive spike-in.

Twist for Element外显子组工作流程是Element AVITI化学的专用解决方案，减轻了线性库转换对其他工作流程步骤的需求。该工作流程将包括Twist的文库制备和与Exome 2.0捆绑的靶标富集以及全面的插入。

The Exome 2.0 delivers best-in-class sequencing due to its high uniformity and low off-target rate. It is designed to detect rare and inherited diseases, as well as germline cancers..

外显子组2.0由于其高均匀性和低脱靶率而提供了同类最佳的测序。它旨在检测罕见和遗传性疾病以及种系癌症。。

If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here.

如果有兴趣了解更多有关Twist for Element、Exome 2.0以及全面的Exome Spike in工作流的信息，请联系这里。

About Element Biosciences, Inc.

关于Element Biosciences，Inc。

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing and other omics technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research.

Element Biosciences是一家多学科的生命科学公司，专注于为研究市场开发破坏性DNA测序和其他组学技术。通过创新测序系统的每个基本元素，element为客户提供了负担得起的高质量数据和改进的用户体验，这反过来将加速科学发现并扩大基因组研究的使用。

To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn and Facebook..

要了解更多有关Element的信息，请访问www.elementbiosciences.com，并在LinkedIn和Facebook上关注我们。。

About Twist Bioscience Corporation

关于Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Twist Bioscience是一家领先且快速发展的合成生物学和基因组学公司，该公司开发了破坏性DNA合成平台，以实现生物学工程的工业化。该平台的核心是一项专有技术，它开创了一种通过在硅芯片上“写入”DNA来制造合成DNA的新方法。

Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.

Twist正在利用其独特的技术制造广泛的基于DNA的合成产品，包括合成基因，用于下一代测序（NGS）制备的工具以及用于药物发现和开发的抗体库。Twist还在DNA和生物制剂药物发现的数字数据存储方面寻求长期机会。

Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research..

Twist生产的产品适用于许多行业，包括医疗保健、工业化学品、农业和学术研究。。

Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram

在Twitter | Facebook | LinkedIn | YouTube | Instagram上关注我们

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

Twist Bioscience关于前瞻性声明的法律公告

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow to save researchers potential downstream sequencing costs by reducing per sample sequencing requirements.

本新闻稿包含前瞻性声明。除历史事实陈述外，本文所载的所有陈述均为前瞻性陈述，反映了管理层根据1995年《私人证券诉讼改革法案》的安全港条款所做出的当前信念和期望，包括但不限于关于扭转要素能力的陈述，Exome 2.0 plus全面的外显子组插入工作流程，通过减少每个样本的测序要求，节省了研究人员潜在的下游测序成本。

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

前瞻性陈述涉及已知和未知的风险、不确定性和其他重要因素，这些因素可能导致Twist Bioscience的实际结果、表现或成就与前瞻性陈述所表达或暗示的任何未来结果、表现或成就有重大差异。

Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of paten.

这些风险和不确定性包括实现Twist Bioscience重组活动预期收益的能力以及减少DNA数据存储投资的能力；吸引新客户、保留和增加现有客户销售额的能力；Twist Bioscience在任何给定时期取得足够收入以实现或维持运营或盈利能力产生的正现金流的能力；快速变化的技术的风险和不确定性以及合成生物学中可能使产品扭曲的广泛竞争生物科学正在发展过时或无竞争力；重要客户保留的不确定性；Twist Bioscience成功整合被收购公司并从收购中获得预期收益的能力；供应链和其他中断；第三方声称侵犯专利的风险。